Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $160.00 | Outperform | Wolfe Research |
| 1/8/2026 | $175.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/21/2025 | $175.00 | Buy | Citigroup |
| 7/21/2025 | $163.00 | Buy | Truist |
| 7/10/2025 | $182.00 | Buy | Goldman |
| 4/15/2025 | $138.00 | Hold → Buy | Needham |
| 4/14/2025 | $137.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 2/11/2025 | $138.00 | Hold | Deutsche Bank |
Conference Call and Webcast Scheduled for Tuesday, May 5SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026. The schedule for the press release and conference call / webcast is as follows:Q1 2026 Press Release: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2026 Conference Call: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-274-8461International Dial-In
INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tardive dyskinesiaHigher continuation with INGREZZA was observed early in treatment and persisted across a six‑month follow‑up periodSAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving INGREZZA® (valbenazine) capsules showed higher treatment persistence compared to those on AUSTEDO XR (deutetrabenazine). The findings are being presented at
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.
8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
SCHEDULE 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
10-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)
3 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)
Wolfe Research initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $160.00
Morgan Stanley downgraded Neurocrine Biosciences from Overweight to Equal-Weight and set a new price target of $175.00
Citigroup initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $175.00
For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con
Conference Call and Webcast Scheduled for Tuesday, May 5SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026. The schedule for the press release and conference call / webcast is as follows:Q1 2026 Press Release: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2026 Conference Call: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-274-8461International Dial-In
VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) and CRENESSITY® (crinecerfont)Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040sNeurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Soleno Therapeutics, Inc.
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, m
SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies. Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 year
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA® franchise. "Mike is an accomplished leader with a strong record of leading high-performing sales and market
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan
SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)
SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)